Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Holmarc Opto-Mechatronics Ltd. Share Price
Day's Range
Low
₹118.15
High
₹137.50
Price Summary
| Previous Close | ₹118.15 |
|---|---|
| Day's Range | ₹118.15 - ₹137.50 |
| Open | ₹129.80 |
| 52 Week Range | ₹60.05 - ₹142.00 |
| Volume | 13,500 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 15.95 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.40 |
| Price/Earning (TTM) | 30.78 |
| TTM EPS (₹) | 4.06 |
| P/E Ratio | 14.78 |
| Book Value(₹) | 4.07 |
| PAT Margin (%) | 9.67 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 18.50 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 371.67 |
| Expenses | N/A | N/A |
| PBT | N/A | 49.35 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 37.35 |
About Holmarc Opto-Mechatronics Ltd.
| Founded | 1993 |
|---|---|
| Managing Director | Jolly Cyriac |
| NSE Symbol | HOLMARC |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,20,831.36 | 1,743.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,42,074.16 | 8,875.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,75,355.29 | 4,502.10 | 3,532.60 - 3,532.60 |
| Zydus Lifesciences Ltd. | 1,13,216.68 | 1,128.20 | 835.50 - 835.50 |
| Lenskart Solutions Ltd. | 1,10,289.40 | 625.20 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,09,132.55 | 7,735.50 | 6,696.50 - 6,696.50 |
| Laurus Labs Ltd. | 1,07,954.38 | 1,963.00 | 902.35 - 902.35 |
| Cipla Ltd. | 1,07,438.71 | 1,325.75 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,03,416.89 | 1,218.55 | 1,101.00 - 1,101.00 |
| Mankind Pharma Ltd. | 94,042.11 | 2,205.35 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Park Medi World informs about disclosure
In continuation to its previous disclosure dated October 14, 2026, Park Medi World has informed that verification has been conducted by the Income Tax Department from October 12, 2026 to October 17, 2026, at some of the premises inter-alia related to the Company, some of its subsidiaries and officials. The details as required under the Listing Regulations read with SEBI circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in ‘Annexure’ as enclosed. The disclosure is also being disseminated on the Company's website at https://www.parkhospital.in/.
The above information is a part of company’s filings submitted to BSE.
Cipla informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informed that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen) (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 19th October, 2026 to 22nd October 2026 (ET). The Inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. The inspection concluded with zero Form 483 observations.
The above information is a part of company’s filings submitted to BSE.
Beta Drugs - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 580.11 | 544.80 | 6.48 | 1138.37 | 1208.05 | -5.77 | 2254.30 | 2202.00 | 2.38 |
| Other Income | 18.59 | 27.43 | -32.23 | 37.26 | 57.18 | -34.84 | 111.43 | 61.92 | 79.96 |
| PBIDT | 82.52 | 74.78 | 10.35 | 202.75 | 179.61 | 12.88 | 396.87 | 376.08 | 5.53 |
| Interest | 6.51 | 29.74 | -78.11 | 22.52 | 57.62 | -60.92 | 118.07 | 47.56 | 148.25 |
| PBDT | 76.01 | 45.04 | 68.76 | 180.23 | 121.99 | 47.74 | 278.80 | 282.82 | -1.42 |
| Depreciation | 26.27 | 23.82 | 10.29 | 51.12 | 44.20 | 15.66 | 96.69 | 74.42 | 29.92 |
| PBT | 49.74 | 21.22 | 134.40 | 129.11 | 77.79 | 65.97 | 182.11 | 208.40 | -12.62 |
| TAX | 12.62 | 6.07 | 107.91 | 32.66 | 20.31 | 60.81 | 38.77 | 54.08 | -28.31 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 37.12 | 15.15 | 145.02 | 96.45 | 57.48 | 67.80 | 143.34 | 154.32 | -7.12 |
| Equity | 111.21 | 100.95 | 10.16 | 111.21 | 100.95 | 10.16 | 101.37 | 100.95 | 0.42 |
| PBIDTM(%) | 14.22 | 13.73 | 3.63 | 17.81 | 14.87 | 19.79 | 17.61 | 17.08 | 3.08 |
Lincoln Pharmaceuticals informs about board meeting
Lenskart Solutions informs about earnings call
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lenskart Solutions has informed that the Company will be hosting an Earnings Call with Analysts/Investors on Wednesday, November 4, 2026 at 05:30 PM (IST) to discuss the Financial Results for the quarter and half-year ended on September 30, 2026. The company has enclosed the pre-registration link for joining the Earnings Call. The above intimation will be made available on the website of the Company at https://www.lenskart.com/corporate/investorrelations.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Holmarc Opto-Mechatronics Ltd. is ₹118.15 as of 2026-10-23.
The market capitalisation of Holmarc Opto-Mechatronics Ltd. is ₹125.62 as of 2026-10-22.
The 1-year return of Holmarc Opto-Mechatronics Ltd. is 5.25% as of 2026-10-23.
The P/E ratio of Holmarc Opto-Mechatronics Ltd. is 14.78 as of 2026-10-23.
The 52-week high and low of Holmarc Opto-Mechatronics Ltd. are ₹142.00 and ₹60.05, respectively, as of 2026-10-23.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
